Weblogic Authors: Yeshim Deniz, Elizabeth White, Michael Meiner, Michael Bushong, Avi Rosenthal

News Feed Item

BIOLASE's CEO Responds to Claims Made by Oracle Partners L.P.

IRVINE, CA -- (Marketwired) -- 05/16/14 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, including the Company's proprietary WaterLase®, and a pioneer in laser surgery in other medical specialties, as well as a distributor of digital radiography, intra oral scanners, and chair-side milling machines and 3-D printers for dentistry, today announced that Federico Pignatelli, the Company's Chairman and Chief Executive Officer, has responded to claims and allegations made by Oracle Partners L.P. ("Oracle") in a press release dated May 14, 2014.

Federico Pignatelli, Chairman and CEO, said, "I would prefer not to respond to Oracle's absurd claims but their press release dated May 14, 2014 is an inappropriate attempt to mislead our stakeholders and accordingly it must be addressed. As such, I would like to bring the following items to the attention of our stakeholders:

  • Oracle has been blatantly trying to gain control of BIOLASE's Board of Directors (our "Board") since September 2013. This is evidenced in a large number of documents BIOLASE has obtained in discovery during our recent litigation against Oracle. It is now apparent to me that Oracle conspired to have Mr. Paul Clark and Mr. Jeffrey Nugent appointed to our Board, all the while purporting that they were uninterested parties. Together with Dr. Fred Moll, who was seemingly working while a BIOLASE's Board Member with Oracle, this very group attempted to illegally gain control of our Board. I believe that once they had control of our Board, their plan was to push through a financing that would be highly dilutive to our other shareholders. Oracle has proposed such a financing to our Board last August and it has been rejected. This type of dilutive financing could essentially pass control of BIOLASE to Oracle without requiring them to put forth a tender offer to our shareholders that would typically result in a premium to market.
  • I believe that the primary goal of the lawsuit filed by Oracle against BIOLASE on March 8th 2014 was to block the public offering under our universal shelf registration statement contemplated by the Board which would dilute Oracle's ownership position.
  • The director dispute arose because Messrs. Clark and Nugent did not properly disclose that they were conspiring with Oracle to gain control of our Board.
  • I believe that Oracle's lawsuit had a dramatic and meaningful impact on our end of quarter sales for the three months ended March 31, 2014. Like most companies that sell capital equipment, a significant portion of our sales closes in the last month of a quarter, and the uncertainty that the lawsuit created regarding the composition of our Board most definitely impacted the decision making process of most of buyers.
  • Despite its representations, Oracle has no experience whatsoever with dental equipment companies and, to the best of my knowledge, has not invested in the dental field prior to their investment in BIOLASE. Oracle's proposed director candidates of Messrs. Clark, Nugent, and Varma and Dr. Moll have had no experience in the dental business or even, with the exception of Dr. Moll, in medical equipment. In fact, their primary experience is in cosmetics, pharmaceuticals, and finance.
  • On several occasions, Oracle's representatives have told me that they actually disliked the dental business because they don't understand it and that they believe we should divest of our long standing dental business in order to concentrate our efforts in the application of our proprietary WaterLase technology in various other medical fields, which Oracle believes present vast opportunities for return on their investment.
  • I trust that the pending decision by the Chancery Court of Delaware will shed light on the true nature of Oracle's attempted takeover of BIOLASE. It is my firm belief that Oracle's lawsuit was an effort to disguise their ultimate goal to gain control of BIOLASE without paying the substantial premium that our stockholders deserve.
  • Oracle itself is a small fund with barely $700 million under management and that has vastly under performed in recent months, while tracking below its piers and Biotech indexes. Oracle is mostly invested in Biotech money losing and illiquid microcaps in which they own large stakes, in several of them along side long time partner Jack Schuler of Crabtree Partners, to control their destiny. I believe that Oracle is looking for publicity by trying to make for itself a "name" as an "activist investor" in the medical field.
  • BIOLASE, under my management, has improved revenues from an annualized run rate of products and services revenue of approximately $20 million based on the nine months ended September 30, 2010, to approximately $56 million for the year ended December 31, 2013. During this period, we expanded our product line from one well outdated WaterLase system to 3 advanced WaterLase systems and several cutting edge diode laser systems alongside a full complement of other truly innovative dental technologies such as ConBeam digital Radiography and the top of the line 3Shape Trio CAD/CAM digital impressions. Further, the newly developed proprietary Galaxy BioMill open architecture chair-side milling system, along with distribution of Stratasys (SSYS) OrthoDesk 3D printing, will be launched for marketing in the current quarter. This is the widest product offerings in BIOLASE's history.
  • In this process of re-structuring and re-launching BIOLASE's entire business into the first Total Technology Solution provider for Dental Practices, BIOLASE incurred a non-GAAP net loss of $13.3 million for the period from October 1, 2010 through March 31, 2014. Considering legal expenses related to the director dispute and shareholder litigation brought by Oracle of $682,000 during the three months ended March 31, 2014, and a one-time charge of approximately $1 million to our reserve for excess and obsolete inventory during the third quarter ended September 30, 2013, which was primarily related to inventory purchases made by prior management, the adjusted non-GAAP net loss for the period from October 1, 2010 through March 31, 2014 is approximately $11.7 million. This 3 year period loss needs to be compared to a non-GAAP net loss of $10.6 million for the nine months only ended September 30, 2010 that BIOLASE experienced right before my becoming the CEO with new management.
  • Further, during the period from October 1, 2010 through March 31, 2014, we invested approximately $14.8 million in engineering and development. Had I halted this continued investment in our future, BIOLASE would have generated adjusted non-GAAP net income, excluding engineering and development, of approximately $3.1 million. The investment in R&D has contributed BIOLASE building the largest array of cutting edge high tech products in its history that we expect to be a strong contributor of imminent and significant future growth.

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 25,500 laser systems. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE®, WaterLase®, and Total Technology Solution™ are registered trademarks or trademarks of BIOLASE, Inc.

Non-GAAP Disclosure
The non-GAAP financial information contained herein are a supplement to the corresponding financial measures prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the Company's on-going core operating performance.

Management believes that the presentation of this non-GAAP financial information provides investors with greater transparency and facilitates comparison of operating results across a broad spectrum of companies with varying capital structures, compensation strategies, derivative instruments, and amortization methods, which provide a more complete understanding of our financial performance, competitive position, and prospects for the future. However, the non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of our business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.

Management uses non-GAAP net (loss) income (defined as net loss before interest, taxes, depreciation and amortization, and stock-based other equity instruments, and other non-cash compensation) in its evaluation of the Company's core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that this non-GAAP financial information reflects an additional way of viewing aspects of our business that, when viewed with our GAAP results, provide a more complete understanding of factors and trends affecting our business.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives, product introductions and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

(financial table follows)

                               BIOLASE, INC.
 Reconciliation of GAAP Net (Loss) Income to Non-GAAP Net (Loss) Income and
                   Adjusted Non-GAAP Net Loss (Unaudited)
                               (in thousands)

                   Three                                   Three
                   Months       Twelve Months Ended        Months
                   Ended           December 31,            Ended
                   March   ----------------------------   December
                 31, 2014    2013      2012      2011     31, 2013   Total
                 --------  --------  --------  --------  --------- --------
GAAP net (loss)
 income          $ (4,887) $(11,482) $ (3,056) $ (4,486) $     174 $(23,737)
   expense, net       230       600       239       305        144    1,518
  Income tax
   (benefit)           24      (164)      111        89          6       66
   expense            175       601       513       695        240    2,224
   other equity
   and other non-
   expense            371     1,965     1,873     2,051        310    6,570
                 --------  --------  --------  --------  --------- --------
Non-GAAP net
 (loss) income     (4,087)   (8,480)     (320)   (1,346)       874  (13,359)
  One time legal
   related to
   dispute and
   brought by
   Oracle             682         -         -         -          -      682
  One time charge
   to increase
   reserve for
   excess and
   inventory            -     1,000         -         -          -    1,000
                 --------  --------  --------  --------  --------- --------
Adjusted non-GAAP
 net (loss)
 income            (3,405)   (7,480)     (320)   (1,346)       874  (11,677)
  Engineering &
   development        973     4,029     4,684     4,311        800   14,797
                 --------  --------  --------  --------  --------- --------
Adjusted non-GAAP
 net (loss)
 income excluding
 engineering &
 development     $ (2,432) $ (3,451) $  4,364  $  2,965  $   1,674 $  3,120
                 ========  ========  ========  ========  ========= ========

For further information, please contact:
Michael Porter
Porter, LeVay & Rose, Inc.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
DXWorldEXPO LLC announced today that the upcoming DXWorldEXPO | CloudEXPO New York event will feature 10 companies from Poland to participate at the "Poland Digital Transformation Pavilion" on November 12-13, 2018.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
JETRO showcased Japan Digital Transformation Pavilion at SYS-CON's 21st International Cloud Expo® at the Santa Clara Convention Center in Santa Clara, CA. The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get...
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
"We are a well-established player in the application life cycle management market and we also have a very strong version control product," stated Flint Brenton, CEO of CollabNet,, in this SYS-CON.tv interview at 18th Cloud Expo at the Javits Center in New York City, NY.
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
Most people haven’t heard the word, “gamification,” even though they probably, and perhaps unwittingly, participate in it every day. Gamification is “the process of adding games or game-like elements to something (as a task) so as to encourage participation.” Further, gamification is about bringing game mechanics – rules, constructs, processes, and methods – into the real world in an effort to engage people. In his session at @ThingsExpo, Robert Endo, owner and engagement manager of Intrepid D...